PRNewsWire
16 Apr 2026, 14:00 UTC · 22w ago
Verdict
Headline takes no side. We score DERM −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pomerantz LLP is investigating Journey Medical Corporation (DERM) for potential securities fraud and unlawful business practices.
More negative than 92% of claims this week
Journey Medical Corporation reported a disconnect between prescription demand for Emrosi and actual realized revenue, attributed to reimbursement timing and co-pay programs.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 81% of claims this week
Journey Medical Corporation's stock price dropped approximately 30% on March 26, 2026, following financial disclosures and management's commentary.
More negative than 67% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities fraud investigation and experienced a 30% stock price drop.
More negative than 88% of ticker scores this week
The company is being investigated by the Pomerantz Law Firm on behalf of investors.
More negative than 88% of ticker scores this week
The company is being investigated by the Pomerantz Law Firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1d ago
+38.9%
Price is moving against the score
$7.36 vs $5.30 close before publication (Apr 15) · not market-adjusted
DERM chart →
